Journal of Pharmaceutics & Drug Delivery Research ISSN: 2325-9604

Research Article, J Pharm Drug Deliv Res Vol: 6 Issue: 1

A QSAR and Docking Study of Selective Estrogen Receptor Modulators (SERMs)

Atefeh Hajiagha Bozorgi1* and Samaneh Kakhki2
1Faculty of Pharmacy, Alborz University of Medical Sciences, Alborz, Iran
2Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
Corresponding author : Atefeh Hajiagha Bozorgi
Department of Medicinal Chemistry, Faculty of Pharmacy, Alborz University of Medical Sciences, Alborz, Iran
Tel: +98-912 32 25 205
E-mail: [email protected]
Received: August 16, 2016 Accepted: November 08, 2016 Published: January 02, 2017
Citation: Bozorgi AH, Kakhki S (2017) A QSAR and Docking Study of Selective Estrogen Receptor Modulators (SERMs). J Pharm Drug Deliv Res 6:1. doi: 10.4172/2325-9604.1000162

Abstract

In recent years, SERMs have gained great attention due to increased breast cancer incidence. So, understanding how they bind to the estrogen receptor is of great importance. On the other hand, inhibition of breast cancer cells isn’t the same for all of these molecules. Understanding how they inhibit cancer cells helps in designing new inhibitors. Here, we developed a QSAR model for the inhibitory activity of MCF-7 cells. The data set had 159 structurally diverse molecules and the obtained model was validated by predicting inhibition of 39 compounds as external set. Developed model has high predictive power characterized by R and R2 values 0.87 and 0.76 respectively. Docking study was also performed to obtain the best conformation that can bind to the receptor. Comparison of these results shows that the essentials for inhibitory activity and binding to the receptor have a little difference.

Keywords: SERMs; QSAR; Docking study; Breast cancer

Track Your Manuscript

Recommended Conferences

Share This Page